Marco Capasso, JD
As General Counsel, Marco is responsible for WCG’s worldwide legal, risk management, and corporate governance. In this capacity, Marco’s oversight includes all legal matters related to the company’s contracts, operations, insurance, intellectual property, privacy, compliance, and finance functions.
Prior to joining WCG, Marco was vice president and assistant general counsel of PAREXEL International, LLC. In this role, Marco served as the primary legal advisor and business partner for PAREXEL’s Study Start-up, Compliance, Quality, Regulatory, Tax, Information Technology and Data Privacy organizations. He also played a critical role in the establishment of PAREXEL’s legal entity in Ireland and was responsible for management of PAREXEL’s legal team in Japan.
Prior to joining PAREXEL, Mr. Capasso was counsel and director at ImClone Systems, a fully owned subsidiary of Eli Lilly and Company. He also spent time with several other global pharmaceutical companies including Dainippon Sumitomo Pharma America (now Sunovion), Eisai Medical Research, and Schering-Plough (now Merck).
Marco’s career before law school was as a clinical researcher in New York. Marco served as a clinical research coordinator at Memorial Sloan-Kettering and Mount Sinai Medical Center where he worked on numerous clinical trials in genetics, internal medicine, and cardiology. Marco is listed as a co-author for his research and has received acknowledgment in numerous peer-reviewed medical journals.
Marco received his J.D. from Rutgers University (Camden) and his B.A. from Columbia University.